CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

March 16, 2021

Conditions
Acute Myeloid Leukemia, Relapsed, Adult
Interventions
DRUG

CDIAG regimen

Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17.

Trial Locations (1)

215006

The First Affliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Jining Medical University

OTHER

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT03985007 - CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter